肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

CLIN CANCER RES：AZD9496治疗ER+/HER2-晚期乳腺癌

2018-08-13 MedSci MedSci原创

乳腺癌AZD9496ER+HER2-
关注

AZD9496是一种口服的雌激素受体α小分子抑制剂，也是雌激素受体α的选择性拮抗剂及降解剂。CLIN CANCER RES近期发表了一篇文章，报道了AZD9496治疗ER+/HER2-晚期乳腺癌的安全性、耐受性、药代动力学特征以及初步的抗肿瘤活性。

AZD9496是一种口服的雌激素受体α小分子抑制剂，也是雌激素受体α的选择性拮抗剂及降解剂。CLIN CANCER RES近期发表了一篇文章，报道了AZD9496治疗ER+/HER2-晚期乳腺癌的安全性、耐受性、药代动力学特征以及初步的抗肿瘤活性。

共有45例患者接受AZD9496治疗，分为剂量递增队列和剂量拓展队列。两个队列中，在增加至下一个剂量水平之前均需检测安全性、有效性及药代动力学。根据CTCAE v4.0对不良反应进行分级。利用RECIST v1.1评估客观肿瘤反应情况。研究结果表明，最常见的不良反应为腹泻（35.6%），疲劳（31.1%）和恶心（22.2%），7例患者出现三级及以上不良反应。3例患者出现剂量限制毒性：150mg BID（肝功能异常），400mg BID（腹泻及肝功能检测异常），600mg BID（腹泻），所有的毒性均可逆。未达到最大耐受剂量。1例患者观察到客观缓解，肿瘤标志物Ca15.3也出现下降。4例患者病情稳定持续12个月。

文章最后认为，AZD9496耐受性及安全性良好，在接受过治疗的ER+/HER2-晚期乳腺癌患者中具有延长疾病稳定时间的作用。

原始出处：
Erika P.Hamilton,Manish R.Patel,et al.A First-in-Human Study of the New Oral Selective Estrogen Receptor Degrader AZD9496 for ER+/HER2- Advanced Breast Cancer.CLIN CANCER RES.August 2018 doi:10.1158/1078-0432.CCR-17-3102

本文系梅斯医学（MedSci）原创编译整理，转载需授权！

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1780266, encodeId=82ed1e80266bd, content=<a href='/topic/show?id=227f308499' target=_blank style='color:#2F92EE;'>#AZD9496#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3084, encryptionId=227f308499, topicName=AZD9496)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sat Jun 22 22:28:00 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982510, encodeId=74081982510e6, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Mon Nov 12 02:28:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714794, encodeId=b58f1e1479471, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Tue Dec 04 09:28:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338491, encodeId=cbea3384917a, content=乳腺癌的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Tue Aug 14 08:23:32 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338463, encodeId=504c33846397, content=新的抗癌药，总是带给患者一丝新的希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7e71713450, createdName=太阳系小猪, createdTime=Tue Aug 14 07:05:54 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338439, encodeId=bc96338439f9, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Aug 14 06:43:44 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338392, encodeId=a6f933839237, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Aug 13 21:31:36 CST 2018, time=2018-08-13, status=1, ipAttribution=)]
    2019-06-22 风铃821

    #AZD9496#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1780266, encodeId=82ed1e80266bd, content=<a href='/topic/show?id=227f308499' target=_blank style='color:#2F92EE;'>#AZD9496#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3084, encryptionId=227f308499, topicName=AZD9496)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sat Jun 22 22:28:00 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982510, encodeId=74081982510e6, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Mon Nov 12 02:28:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714794, encodeId=b58f1e1479471, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Tue Dec 04 09:28:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338491, encodeId=cbea3384917a, content=乳腺癌的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Tue Aug 14 08:23:32 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338463, encodeId=504c33846397, content=新的抗癌药，总是带给患者一丝新的希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7e71713450, createdName=太阳系小猪, createdTime=Tue Aug 14 07:05:54 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338439, encodeId=bc96338439f9, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Aug 14 06:43:44 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338392, encodeId=a6f933839237, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Aug 13 21:31:36 CST 2018, time=2018-08-13, status=1, ipAttribution=)]
    2018-11-12 luwei00

    #HER2-#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1780266, encodeId=82ed1e80266bd, content=<a href='/topic/show?id=227f308499' target=_blank style='color:#2F92EE;'>#AZD9496#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3084, encryptionId=227f308499, topicName=AZD9496)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sat Jun 22 22:28:00 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982510, encodeId=74081982510e6, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Mon Nov 12 02:28:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714794, encodeId=b58f1e1479471, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Tue Dec 04 09:28:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338491, encodeId=cbea3384917a, content=乳腺癌的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Tue Aug 14 08:23:32 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338463, encodeId=504c33846397, content=新的抗癌药，总是带给患者一丝新的希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7e71713450, createdName=太阳系小猪, createdTime=Tue Aug 14 07:05:54 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338439, encodeId=bc96338439f9, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Aug 14 06:43:44 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338392, encodeId=a6f933839237, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Aug 13 21:31:36 CST 2018, time=2018-08-13, status=1, ipAttribution=)]
    2018-12-04 12498e5fm22(暂无昵称)

    #AZ#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1780266, encodeId=82ed1e80266bd, content=<a href='/topic/show?id=227f308499' target=_blank style='color:#2F92EE;'>#AZD9496#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3084, encryptionId=227f308499, topicName=AZD9496)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sat Jun 22 22:28:00 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982510, encodeId=74081982510e6, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Mon Nov 12 02:28:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714794, encodeId=b58f1e1479471, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Tue Dec 04 09:28:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338491, encodeId=cbea3384917a, content=乳腺癌的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Tue Aug 14 08:23:32 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338463, encodeId=504c33846397, content=新的抗癌药，总是带给患者一丝新的希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7e71713450, createdName=太阳系小猪, createdTime=Tue Aug 14 07:05:54 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338439, encodeId=bc96338439f9, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Aug 14 06:43:44 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338392, encodeId=a6f933839237, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Aug 13 21:31:36 CST 2018, time=2018-08-13, status=1, ipAttribution=)]
    2018-08-14 liumin1987

    乳腺癌的治疗。

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1780266, encodeId=82ed1e80266bd, content=<a href='/topic/show?id=227f308499' target=_blank style='color:#2F92EE;'>#AZD9496#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3084, encryptionId=227f308499, topicName=AZD9496)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sat Jun 22 22:28:00 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982510, encodeId=74081982510e6, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Mon Nov 12 02:28:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714794, encodeId=b58f1e1479471, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Tue Dec 04 09:28:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338491, encodeId=cbea3384917a, content=乳腺癌的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Tue Aug 14 08:23:32 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338463, encodeId=504c33846397, content=新的抗癌药，总是带给患者一丝新的希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7e71713450, createdName=太阳系小猪, createdTime=Tue Aug 14 07:05:54 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338439, encodeId=bc96338439f9, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Aug 14 06:43:44 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338392, encodeId=a6f933839237, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Aug 13 21:31:36 CST 2018, time=2018-08-13, status=1, ipAttribution=)]
    2018-08-14 太阳系小猪

    新的抗癌药，总是带给患者一丝新的希望

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1780266, encodeId=82ed1e80266bd, content=<a href='/topic/show?id=227f308499' target=_blank style='color:#2F92EE;'>#AZD9496#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3084, encryptionId=227f308499, topicName=AZD9496)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sat Jun 22 22:28:00 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982510, encodeId=74081982510e6, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Mon Nov 12 02:28:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714794, encodeId=b58f1e1479471, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Tue Dec 04 09:28:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338491, encodeId=cbea3384917a, content=乳腺癌的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Tue Aug 14 08:23:32 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338463, encodeId=504c33846397, content=新的抗癌药，总是带给患者一丝新的希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7e71713450, createdName=太阳系小猪, createdTime=Tue Aug 14 07:05:54 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338439, encodeId=bc96338439f9, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Aug 14 06:43:44 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338392, encodeId=a6f933839237, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Aug 13 21:31:36 CST 2018, time=2018-08-13, status=1, ipAttribution=)]
    2018-08-14 1209e435m98(暂无昵称)

    学习了，谢谢分享

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1780266, encodeId=82ed1e80266bd, content=<a href='/topic/show?id=227f308499' target=_blank style='color:#2F92EE;'>#AZD9496#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3084, encryptionId=227f308499, topicName=AZD9496)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3307462, createdName=风铃821, createdTime=Sat Jun 22 22:28:00 CST 2019, time=2019-06-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1982510, encodeId=74081982510e6, content=<a href='/topic/show?id=da628e19d5' target=_blank style='color:#2F92EE;'>#HER2-#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8719, encryptionId=da628e19d5, topicName=HER2-)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e093393, createdName=luwei00, createdTime=Mon Nov 12 02:28:00 CST 2018, time=2018-11-12, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1714794, encodeId=b58f1e1479471, content=<a href='/topic/show?id=021230e312' target=_blank style='color:#2F92EE;'>#AZ#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3073, encryptionId=021230e312, topicName=AZ)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=9e5031899089, createdName=12498e5fm22(暂无昵称), createdTime=Tue Dec 04 09:28:00 CST 2018, time=2018-12-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338491, encodeId=cbea3384917a, content=乳腺癌的治疗。, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://cdnapi.center.medsci.cn/medsci/head/2018/07/16/3b24606172648eea459125cb74754afe.jpg, createdBy=6c022216608, createdName=liumin1987, createdTime=Tue Aug 14 08:23:32 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338463, encodeId=504c33846397, content=新的抗癌药，总是带给患者一丝新的希望, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=d7e71713450, createdName=太阳系小猪, createdTime=Tue Aug 14 07:05:54 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338439, encodeId=bc96338439f9, content=学习了，谢谢分享, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7c592194322, createdName=1209e435m98(暂无昵称), createdTime=Tue Aug 14 06:43:44 CST 2018, time=2018-08-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=338392, encodeId=a6f933839237, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=0aa31415219, createdName=orangesking, createdTime=Mon Aug 13 21:31:36 CST 2018, time=2018-08-13, status=1, ipAttribution=)]
    2018-08-13 orangesking

    好

    0

相关资讯

JNCI；建议对三阴性乳腺癌进行多基因遗传肿瘤panel检测

采用遗传肿瘤基因panel检测胚系突变可以发现乳腺癌的高风险人群。然而，与三阴性乳腺癌（TNBC）发表风险相关的基因目前尚未明确，除BRCA1突变外，尚未确立其他的易感基因。近日，发布在JNCI的一项研究旨在确定与TNBC高风险相关的基因检测panel。

Int J Cancer：哈佛科学家每天吃大量十字花科蔬菜与患乳腺癌风险降低11% 有关

最近，发表在《国际癌症杂志》上的一项研究评估了特定果蔬与乳腺癌患病风险之间的联系。研究发现，每天多吃蔬果的女性比少吃蔬果的女性患乳腺癌的风险降低了8.5%。其中，多吃十字花科蔬菜及黄色（橙色）蔬菜，与女性患乳腺癌的风险降低11%相关。

乳腺癌早筛应该“因地制宜”！

据2018癌症统计数据显示，我国女性乳腺癌发病率在20岁以后随年龄迅速上升,并于55~60岁左右达到高峰，死亡率随年龄的增长逐渐升高。女性一生中患乳腺癌的概率为10%，北京做的一项研究发现，仅有5.2%新发乳腺癌病例是通过定期乳房X线筛查发现的，而82.1%的女性发现患乳腺癌时已经有明显的症状了。而目前早期乳腺癌患者术后5年生存率已达到90%以上，随着乳腺癌诊疗技术的不断发展进步，实现临床治愈的患

lancet oncol：阿帕替尼联合依托泊苷用于铂类耐受性/难治性乳腺癌的效果和安全性

抗血管生成疗法与化疗相结合，可提高铂类耐药性卵巢癌患者的预后。阿帕替尼是一种口服的酪氨酸激酶抑制剂，可选择性抑制VEGF受体2。现有研究人员对阿帕替尼与口服依托泊苷联合用于铂类耐药性或难治性的卵巢癌患者的疗效和安全性进行评估。研究人员开展一前瞻性的单臂的2期试验，在中国中山大学癌症中心招募18-70岁的铂类耐药性或难治性的门诊卵巢癌患者。予以阿帕替尼（起始剂量500mg 1/日，连续用药）、依托泊

施一公、颜宁课题组发表“结构生物学”全新成果、乳腺癌细胞早在胎儿细胞期就已“埋下伏笔”、Nature子刊颁布CAR-T疗法指南……| BioWeek一周事

两篇Science！施一公、颜宁课题组发表“结构生物学”最新成果；震惊！乳腺癌细胞早在胎儿细胞期就已“埋下伏笔”；为改善心脏健康，Nature子刊：给肠道菌“下药”；辨色识癌！MIT这种新技术可有效预测化疗药效果；Nature子刊颁布CAR-T疗法指南，关联儿童急性淋巴细胞白血病；重磅！两篇Nature共同揭示：新型肺细胞…………更多资讯，请跟随小编一起回顾吧。

Brit J Cancer：乳腺癌患者内乳链照射和蒽环类化疗后的心血管疾病发病率

由此可见，接受基于蒽环类化疗和接受大量平均心脏剂量暴露IMC照射的女性大大增加了几种CVD的发生率，筛查可能适合某些BC患者群体。